Literature DB >> 9365127

An atypical presentation for primary sclerosing cholangitis.

V A Luketic1, D A Gomez, A J Sanyal, M L Shiffman.   

Abstract

We describe the clinical course of a group of patients with primary sclerosing cholangitis who at presentation were diagnosed to have autoimmune hepatitis. The history of one such patient is described in detail. We also compare this atypical sclerosing cholangitis (group I) to typical sclerosing cholangitis (group II) and to autoimmune hepatitis with (group III) and without (group IV) cholestasis. At presentation, mean AST in groups I and III was similar and significantly higher than in group II (P < 0.05). Mean ALP was higher in sclerosing cholangitis than in autoimmune hepatitis but not significantly so. Triaditis was present in all patients in groups I, III, and IV. Piecemeal necrosis and multilobular collapse/fibrosis were equally frequent in groups I, III, and IV. Only the response to corticosteroids helped differentiate among groups. Groups III and IV responded by normalizing AST. In group I, AST improved, but never became normal. As ALP became disproportionately abnormal (ALP-predominant pattern), cholangiography was performed, and the diagnosis of primary sclerosing cholangitis was made in all group I patients. We recommend that cholangiography be performed early in patients with suspected autoimmune hepatitis who partially respond to corticosteroids and develop an ALP-predominant pattern.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365127     DOI: 10.1023/a:1018845829198

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

Review 1.  Role of immune factors in the pathogenesis of primary sclerosing cholangitis.

Authors:  R W Chapman
Journal:  Semin Liver Dis       Date:  1991-02       Impact factor: 6.115

2.  Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

Authors:  R H Duerr; S R Targan; C J Landers; N F LaRusso; K L Lindsay; R H Wiesner; F Shanahan
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

3.  Meeting report: International Autoimmune Hepatitis Group.

Authors:  P J Johnson; I G McFarlane
Journal:  Hepatology       Date:  1993-10       Impact factor: 17.425

Review 4.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

5.  Natural history, clinical features, and treatment of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Semin Liver Dis       Date:  1984-02       Impact factor: 6.115

6.  Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.

Authors:  P Michieletti; I R Wanless; A Katz; P J Scheuer; S J Yeaman; M F Bassendine; J M Palmer; E J Heathcote
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

7.  Current concepts. Primary sclerosing cholangitis.

Authors:  N F LaRusso; R H Wiesner; J Ludwig; R L MacCarty
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

8.  Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis.

Authors:  M Rabinovitz; A J Demetris; C F Bou-Abboud; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

9.  The combination of prednisone and colchicine in patients with primary sclerosing cholangitis.

Authors:  K D Lindor; R H Wiesner; L J Colwell; B Steiner; S Beaver; N F LaRusso
Journal:  Am J Gastroenterol       Date:  1991-01       Impact factor: 10.864

10.  Liver transplantation for sclerosing cholangitis.

Authors:  S Narumi; J P Roberts; J C Emond; J Lake; N L Ascher
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more
  4 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 3.  Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis.

Authors:  Christoph Schramm; Ansgar W Lohse
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 4.  Overlap syndromes of autoimmune hepatitis: what is known so far.

Authors:  Marilena Durazzo; Alberto Premoli; Sharmila Fagoonee; Rinaldo Pellicano
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.